Stock Analysis
Camurus Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Camurus (STO:CAMX) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr479.6m (up 25% from 3Q 2023).
- Net income: kr129.3m (up 50% from 3Q 2023).
- Profit margin: 27% (up from 23% in 3Q 2023). The increase in margin was driven by higher revenue.
- EPS: kr2.21 (up from kr1.56 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Camurus EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) exceeded analyst estimates by 32%.
Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden.
Performance of the Swedish Pharmaceuticals industry.
The company's shares are up 2.5% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Camurus has 2 warning signs we think you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:CAMX
Camurus
A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.